• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Drugs for Neglected Diseases initiative unveils new plan for neglected patients

Basel, Switzerland — 7 Sep 2015
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Aims to Deliver 16-18 Treatments for Up to 10 Diseases with EUR 650 Million
After having built the world’s largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi’s portfolio.
[English] [Español] [Français] [Português]

As part of its updated Business Plan for the period 2015-2023, DNDi remains committed to developing treatments for African sleeping sickness, leishmaniasis, and Chagas disease as well as filarial diseases and paediatric HIV. Having recently transferred its malaria activities to the Medicines for Malaria Venture (MMV), DNDi will soon be launching new research and development (R&D) projects for hepatitis C and mycetoma, two very different diseases that share, with other important global health issues such as anti-microbial resistance, one key challenge: the existing system of biomedical innovation has failed to deliver safe, effective, quality products that are affordable to poor populations.

‘New threats are emerging at breakneck speed in today’s rapidly changing global health R&D landscape’, said Dr Bernard Pécoul, Executive Director of DNDi. ‘DNDi will remain focused on reaching our treatment targets for the most neglected diseases, but we are now in a position to apply new R&D models, where patient needs drive drug development over profits, and where prices of drugs are delinked from the cost of their development,’ he added.

The Business Plan 2015-2023 was elaborated through a 24-month process and in-depth consultation with DNDi’s founding partners, governments, key stakeholders, and experts in global health research. It was approved by the Board of Directors in June 2015. The new plan emphasizes DNDi’s commitment to addressing the needs of neglected patients, while allowing for more flexibility to extend the scope of diseases to address current and future unmet and/or urgent patient needs as they arise. A range of operating and support models has been designed to ensure DNDi’s engagement is tailored and appropriate to the need.

For example, the high-cost of a new generation of drugs for hepatitis C has become one of the world’s most pressing and high-profile public health challenges, leaving millions of patients behind. To develop an affordable public health tool for hepatitis C, DNDi will conduct clinical trials for combinations consisting of recently approved drugs and clinical-stage compounds in middle-income countries. For mycetoma, DNDi will test a promising drug candidate for this devastating illness for which there has been virtually no R&D – leaving patients to suffer with toxic and ineffective drugs. To help address the global threat posed by anti-microbial resistance, DNDi will create an internal task force, in collaboration with WHO, to assess the potential of an incubator to house a new initiative focused on developing antibiotics.

DNDi will continue developing its pipeline of over 30 projects for the most neglected diseases. By its 20th anniversary in 2023, DNDi aims to deliver 16 to 18 new treatments with an estimated total budget of EUR 650 million. Importantly, DNDi will use its own experience to forcefully advocate for a global R&D framework that guarantees both innovation and equitable patient access to health technologies.

‘The Ebola crisis showed the world the need for highly effective collaborations and timely response,’ said Professor Marcel Tanner, Chair of the Board of Directors, DNDi. ‘As the organization matures, DNDi will continue to learn, innovate, and adapt its operational models to guarantee that R&D capacity is built where needed while continuously identifying and addressing neglected patients’ needs through the best science.’

Short DNDi Business Plan video

About the Drugs for Neglected Diseases initiative (DNDi)
A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected diseases, in particular leishmaniasis, human African trypanosomiasis, Chagas disease, specific filarial infections, paediatric HIV, mycetoma, and hepatitis C. Since its inception in 2003, DNDi has delivered six treatments: two fixed-dose antimalarials (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness, sodium stibogluconate and paromomycin (SSG&PM) combination therapy for visceral leishmaniasis in Africa, a set of combination therapies for visceral leishmaniasis in Asia, and a paediatric dosage form of benznidazole for Chagas disease. DNDi has established regional disease-specific platforms, which bring together partners in disease-endemic countries to strengthen existing clinical research capacity, as well as to build new capacity where necessary. www.dndi.org

Press Contacts
USA – Ilan Moss
imoss@dndi.org
+1 646 266 5216

India – Manisha Sharma
msharma@dndi.org
+91 9711 009 088

Europe – Gabrielle Landry
glandry@dndi.org
+41 79 309 3910

Africa – Linet Atieno Otieno
latieno@dndi.org
+25 473 362 4206

Policy advocacy Funding Partnership Strengthening Capacities Registration & access Chagas disease Filaria: river blindness Hepatitis C Mycetoma Paediatric HIV Visceral leishmaniasis

Read, watch, share

Loading...
Woman standing in front of a house
Press releases
2 Feb 2023

Dutch government renews support to DNDi projects on poverty-related diseases that disproportionately impact women

Statements
1 Feb 2023

DNDi interventions at the 152nd session of the WHO Executive Board

Young man sitting in hospital setting
News
30 Jan 2023

It’s time medical innovation reached the 1.7 billion people affected by neglected tropical diseases: World NTD Day 2023

Film Poster Voices of Leishmaniasis: Shushi from India
Videos
25 Jan 2023

Voices of leishmaniasis: Shishu from India

Child receiving treatment
News
20 Jan 2023

DNDi’s 20th year of bringing the best science for the most neglected

Child affected by dengue and her mother at their home in Bangkok, Thailand.
Stories
16 Dec 2022

2022: Six advances in neglected disease research to remember

Statements
2 Dec 2022

DNDi‘s comments on the conceptual zero draft for the consideration of the Intergovernmental Negotiating Body at INB3

Healthcare workers discussing in hospital setting
Press releases
1 Dec 2022

DNDi partners in a new NIHR-funded Global Health Research Group on HIV-associated Fungal Infections (IMPRINT)

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo